Navigation Links
Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
Date:6/3/2010

of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases.  Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFNs) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at http://www.sangamo.com/.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sangamo BioSciences and Collaborators Present Data in Fifteen Presentations Highlighting Broad Therapeutic Applications of ZFP Technology
2. Sangamo BioSciences Announces Presentation at Two Upcoming Investor Conferences
3. Sangamo BioSciences Announces Presentation at Cowen and Company Health Care Conference
4. Sangamo BioSciences Reports Fourth Quarter and Full Year 2009 Financial Results
5. Sangamo BioSciences Announces Presentation at BIO CEO & Investor Conference
6. Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
7. Sangamo BioSciences Announces Presentation at Merriman Curhan Fords Investor Summit 2009
8. Sangamo BioSciences Announces Third Quarter 2009 Conference Call and Webcast
9. Sangamo Announces Pricing of Public Offering of Common Stock
10. Sigma-Aldrich(R) and Sangamo BioSciences Announce Major Expansion of ZFP Technology License Agreement
11. Sangamo BioSciences Announces Presentation at the UBS Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... 2015 According to a new ... (Mesh/Tissue patch, Allograft, Xenograft, Suture Anchor, Interference Screws, Laparoscopic ... Breast augmentation) - Global Forecast to 2019", published by ... reach $14.7 Billion in 2019 from $10.3 Billion in ... to 2019. Browse 70 market data ...
(Date:3/6/2015)... --  Senomyx , Inc. (NASDAQ: SNMX ), ... discover, develop, and commercialize novel flavor ingredients for the ... Poyhonen , the Company,s President and Chief Executive Officer, ... Chief Financial Officer, will present an overview of Senomyx,s ... at 2:00 p.m. Eastern Time (11:00 a.m. Pacific Time) ...
(Date:3/5/2015)... NEW YORK , March 5, 2015  DuPont ... J.P. Morgan Aviation, Transportation and Industrials Conference held today ... Vice President Matthew L. Trerotola discussed strategy, ... Advanced Materials segments for DuPont.  Strengthening and growing the ... of the three areas of strategic priority for DuPont. ...
(Date:3/5/2015)... BioPlus Specialty Pharmacy (BioPlus) announces the hiring ... of Managed Care. In this role, Damm will build ... nation’s leading specialty pharmacies. , Damm, who is based ... pharmacy and biotech experience to his new position with ... and Pfizer. Prior to working in Healthcare Damm served ...
Breaking Biology Technology:Soft Tissue Repair Market worth $14.7 Billion in 2019 2Soft Tissue Repair Market worth $14.7 Billion in 2019 3Soft Tissue Repair Market worth $14.7 Billion in 2019 4SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE THE 27TH ANNUAL ROTH CONFERENCE 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4BioPlus Specialty Pharmacy Announces Hiring of New Vice President of Managed Care: Jamie Damm 2
... Feb. 12 Pharmacyclics, Inc.,(Nasdaq: PCYC ), ... clinical testing and several late stage preclinical programs,announced today ... new board,member. , Robert W. ... CEO of the,company after acting as interim CEO for ...
... Company Exceeds Sales and Earnings GuidanceCompany Reiterates 2009 Earnings ... 12 Cephalon, Inc . (Nasdaq: ... $1.943 billion, compared to sales of $1.727 billion for ... income per common share for the full year 2008 ...
... Inc., announced,today the appointment of John P. Walker as ... of Directors. Walker was most recently the,Chairman and ... in January 2009. , (Photo: ... Bio is focused on the development of induced pluripotent ...
Cached Biology Technology:Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 2Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 3Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 4Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 5Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth 6Cephalon's New Product Launches Pace Record 2008 Sales 2Cephalon's New Product Launches Pace Record 2008 Sales 3Cephalon's New Product Launches Pace Record 2008 Sales 4Cephalon's New Product Launches Pace Record 2008 Sales 5Cephalon's New Product Launches Pace Record 2008 Sales 6Cephalon's New Product Launches Pace Record 2008 Sales 7Cephalon's New Product Launches Pace Record 2008 Sales 8Cephalon's New Product Launches Pace Record 2008 Sales 9Cephalon's New Product Launches Pace Record 2008 Sales 10Cephalon's New Product Launches Pace Record 2008 Sales 11Cephalon's New Product Launches Pace Record 2008 Sales 12Cephalon's New Product Launches Pace Record 2008 Sales 13Cephalon's New Product Launches Pace Record 2008 Sales 14Cephalon's New Product Launches Pace Record 2008 Sales 15Cephalon's New Product Launches Pace Record 2008 Sales 16Cephalon's New Product Launches Pace Record 2008 Sales 17Cephalon's New Product Launches Pace Record 2008 Sales 18Cephalon's New Product Launches Pace Record 2008 Sales 19Cephalon's New Product Launches Pace Record 2008 Sales 20Cephalon's New Product Launches Pace Record 2008 Sales 21iZumi Bio, Inc., Appoints John Walker as Chief Executive Officer 2
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:2/12/2015)... 12, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile commerce ... 62/113114 for DISTRIBUTED METHOD AND SYSTEM TO ... patent further establishes NXT-ID,s position in the emerging "Internet ... the ability for multiple devices to collaborate with one ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America recently ... for carbon nanotube (CNT) macrostructures, including sheets, yarns and ... (UTD). Leveraging the vast industrial resources of ... Japan , Lintec of America is forming the ... TX , focusing on scaling up the manufacturing ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 2NXT-ID Patents Collaborative Services to Enable the "Internet of Things" 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... Aug. 5, 2013 - For a new study in ... how different concentrations of lipids affect growth performance in ... of lipids affect pigs. According to the researchers, ... absorption because swine genetics have improved over the years. ...
... University of Illinois scientists have evidence that lifelong exposure ... colon cancer by repressing a signal that leads to accelerated ... our study, we report a change in the expression of ... Chen, a U of I professor of food science and ...
... interact with one anotherand not just today. Scientists are studying ... the world in the ancient past and to identify ways ... to a new study published in the August 2 issue ... throughout Earth,s history, but the recent rate of global warming ...
Cached Biology News:Researchers re-evaluate swine nutrition 2Scientists learn how soy foods protect against colon cancer 2Looking to the past to predict the future of climate change 2